Are you more likely today to recommend active surveillance for selected patients with low-risk prostate cancer than you were five years ago?

Evidence is accumulating that active surveillance is an appropriate way to manage low-risk prostate cancer in selected men, with curative treatment delayed until it is warranted by indicators of disease progression. This evidence includes data showing that active surveillance does not cause a significant increase in prostate-cancer mortality compared with immediate treatment. In fact, an independent panel of the National Institutes of Health in December 2011 concluded that active surveillance is a viable option that should be offered to patients with low-risk prostate cancer.

Renal & Urology News wants to know how urologists view active surveillance today compared with five years ago. Please take a few moments to answer our latest poll question:

Are you more likely today to recommend active surveillance for selected patients with low-risk prostate cancer than you were five years ago?
Leave a comment below on why you chose your answer. If your answer doesn’t match one of our choices, please let us know why.

From the April 01, 2012 Issue of Renal and Urology News